BioPharma Resources

Drug Trial Radar · NCT07623161

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK-226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Dec 7, 2029

Study completion Mar 30, 2034

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness, improves symptoms related to MF, and helps participants do physical activities more easily. The study also aims to find out how elritercept affects the bone marrow, the spleen, and whether participants develop antibodies to the study drug. The study will also check how safe elritercept is compared to placebo, and if elritercept stays safe over a long period of time. Participants will receive study treatment for at least 9 months (36 weeks). After this period, participants who received placebo will have the option to switch to elritercept.

Conditions

  • Myelofibrosis
  • Anemia

Interventions

  • PlaceboDrug

    Elritercept-matching placebo

  • ElriterceptDrug

    Elritercept, SC, injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Who Are Red Blood Cell-Transfusion Independent (RBC-TI) for Any Consecutive Greater Than or Equal to (≥) 12-Week Period During the 36-Week Double-Blinded Treatment PeriodTime frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

Locations

214 sites in 31 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Not yet recruiting

  • Los Angeles Cancer Network

    Glendale, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Whittier, California · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Not yet recruiting

  • Advanced Research, LLC

    Coral Springs, Florida · Recruiting

  • Bioresearch Partners

    Miami, Florida · Recruiting

  • AdventHealth - Cancer Institute - Orlando

    Orlando, Florida · Not yet recruiting

  • Florida Clinical Trials Group

    Tamarac, Florida · Recruiting

  • Moffit Cancer Center

    Tampa, Florida · Not yet recruiting

  • Emory University

    Atlanta, Georgia · Not yet recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Not yet recruiting

  • Univ of Michigan

    Ann Arbor, Michigan · Withdrawn

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • St. Vincent Regional Hospital Cancer Centers

    Billings, Montana · Recruiting

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Not yet recruiting

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Withdrawn

  • Duke Blood Cancer Center

    Durham, North Carolina · Not yet recruiting

  • Novant Health

    Winston-Salem, North Carolina · Not yet recruiting

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Withdrawn

  • Cleveland Clinic

    Cleveland, Ohio · Not yet recruiting

  • Oregon Health and Science University

    Portland, Oregon · Not yet recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Not yet recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Allegheny Health Network Cancer Institute - West Penn Hospital Location

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Not yet recruiting

  • Baptist Clinical Research Institute

    Memphis, Tennessee · Withdrawn

  • Vanderbilt-Ingram Cancer Center (VICC)-Nashville

    Nashville, Tennessee · Not yet recruiting

  • Next Innovative Clinical Research

    Baytown, Texas · Withdrawn

  • Baylor University Medical Center

    Dallas, Texas · Withdrawn

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • The University of Utah-Huntsman Cancer Institute

    Houston, Texas · Not yet recruiting

  • LUMI Research

    Houston, Texas · Recruiting

  • University of Washington

    Seattle, Washington · Not yet recruiting

  • Hospital Aleman (HA) Deutsches Hospital

    Buenos Aires, Argentina · Not yet recruiting

  • BRCR Global

    Córdoba, Argentina · Not yet recruiting

  • Hospital Universitario Austral

    Pilar, Buenos Aires, Argentina · Not yet recruiting

  • Swiss Medical Center Barrio Parque

    Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina · Not yet recruiting

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Santa Fe Province, Argentina · Not yet recruiting

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.